

CIPHERGEN BIOSYSTEMS INC

Form 8-K

July 12, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549-1004  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934  
DATE OF REPORT (Date of earliest event reported): JULY 11, 2007  
CIPHERGEN BIOSYSTEMS, INC.  
(Exact name of Registrant as specified in its charter)**

Delaware  
(State or other jurisdiction of  
incorporation or organization)

000-31617  
(Commission  
File Number)  
6611 Dumbarton Circle  
Fremont, CA 94555  
(Address of principal executive offices)  
(510) 505-2100

33-059-5156  
(I.R.S. Employer  
Identification Number)

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (7 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

ITEM 7.01 OTHER EVENTS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

ITEM 7.01 OTHER EVENTS

On July 11, 2007, CIPHERGEN issued a press release announcing that the company received from the United States Patent and Trademark Office a notice of intent to issue a Reexamination Certificate of U.S. patent no. 6,734,022, which is directed to a fundamental process of SELDI mass spectrometry. Upon reissuance of the patent, Bio-Rad Laboratories is to pay CIPHERGEN \$2.0 million pursuant to the terms of the Asset Purchase Agreement entered into in connection with the sale of CIPHERGEN's instrumentation business to Bio-Rad on November 13, 2006.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) EXHIBITS.

EXHIBIT NO.	DESCRIPTION
99.1	Press release issued by CIPHERGEN Biosystems, Inc. on July 11, 2007

---

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CIPHERGEN BIOSYSTEMS, INC.  
(Registrant)

Date: July 12, 2007

By: /s/ DEBRA A. YOUNG  
Debra A. Young  
Chief Financial Officer

---

**Table of Contents**

EXHIBIT INDEX

EXHIBIT NUMBER	DESCRIPTION
99.1	Press release issued by CIPHERGEN Biosystems, Inc. on July 11, 2007